Valuation: Avalo Therapeutics, Inc.

Market Cap 420M 375M 345M 313M 594M 39.4B 609M 4.13B 1.65B 21.1B 1.58B 1.54B 66.44B P/E 2026 *
-3.01x
P/E 2027 * -2.94x
Enterprise Value -15.83M -14.13M -13M -11.8M -22.36M -1.48B -22.91M -155M -61.98M -794M -59.4M -58.13M -2.5B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.78%
Yield 2026 *
0.16%
Yield 2027 * 0.01%
1 day+1.79%
1 week+0.14%
Current month+1.26%
1 month-45.17%
3 months-63.28%
6 months-64.15%
Current year-60.02%
1 week 6.53
Extreme 6.5315
7.59
1 month 6.53
Extreme 6.53
13.69
Current year 6.53
Extreme 6.53
24.27
1 year 6.53
Extreme 6.53
24.27
3 years 3.39
Extreme 3.39
34.46
5 years 3.39
Extreme 3.39
6,710.35
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 13/02/2022
Director of Finance/CFO 42 13/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 07/08/2022
Director/Board Member 78 11/10/2020
Director/Board Member 55 27/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

1,322 0.0025%
30/09/26 Free

Director

1,109 0.0021%
30/09/26 Free

Director

1,352 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
+1.58%+0.14%-52.28%-66.54% 420M
+0.01%+8.40%+58.48%+69.01% 68.22B
+1.41%+9.89%+16.32%+90.80% 59.82B
-0.17%+1.10%+23.48%+97.07% 56.07B
+0.16%+17.55%+26.76%+109.58% 47.67B
-1.16%+4.95%+29.36%+40.63% 45.95B
-1.68%+1.54%+214.39%+900.58% 43.29B
-0.47%+9.38%+27.53%+52.40% 35.66B
-0.70%-1.80%+94.72%+69.62% 34.73B
+0.57%+11.06%-39.56%+388.38% 25.47B
Average -0.00%+5.65%+39.92%+175.15% 42B
Weighted average by Cap. -0.13%+6.17%+51.35%+181.67%

Financials

2026 *2027 *
Net sales - -
Net income -101M -89.89M -82.72M -75.07M -142M -9.44B -146M -990M -394M -5.05B -378M -370M -15.92B -126M -112M -103M -93.56M -177M -11.76B -182M -1.23B -492M -6.3B -471M -461M -19.84B
Net Debt -436M -389M -358M -325M -616M -40.89B -632M -4.29B -1.71B -21.89B -1.64B -1.6B -68.94B -321M -287M -264M -239M -454M -30.09B -465M -3.15B -1.26B -16.11B -1.21B -1.18B -50.74B
Projected Income Statement - Annual - Avalo Therapeutics, Inc.
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Employees
33
Date Price Change Volume
10/11/26 US$7.230 -0.55% 2,327,978
09/11/26 US$7.270 +4.91% 2,803,819
06/11/26 US$6.930 +4.52% 1,112,295
05/11/26 US$6.630 -6.22% 1,258,173
04/11/26 US$7.070 -2.48% 1,378,594
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Avalo Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
7.270USD
Average target price
34.80USD
Spread / Average Target
+378.68%
  1. Stock Market
  2. Stocks
  3. AVTX Stock